Filing Flows › Xeris Biopharma Holdings (XERS) › Q1 2026
Xeris Biopharma Holdings (XERS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Xeris Biopharma Holdings (XERS) reported revenue of $83.1M for the first quarter 2026 (Q1 2026), +38% from a year earlier and -3% from the quarter before. Operating margin was 9.5%, net earnings $2.2M (2.7% of revenue).
Xeris Biopharma Holdings, Q1 2026: revenue $83.1M (+38% year over year), operating margin 9.5%, net earnings $2.2M, operating cash flow $9.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $83.1M | -3% | +38% |
| Operating profit | $7.9M | -53% | — |
| Net earnings | $2.2M | -80% | — |
| Operating cash flow | $9.9M | -51% | — |
What changed
Revenue was $83.1M in Q1 2026, up 38% year over year and down 3% from the previous quarter. Recorlev was the largest line at 60% of revenue. Recorlev added $24.2M year over year (up 95%), 105% of the total change. Royalty, contract and other revenue declined 71%.
Operating profit was $7.9M, a 9.5% margin (up 14.7 points year over year). Total costs grew 19% against revenue growth of 38%. The fastest-growing cost line was Cost of revenue (+21%). Net earnings were $2.2M. The effective tax rate was 0.0%.
Operating cash flow was $9.9M, 442% of net earnings. Non-cash charges added back $337K of depreciation and amortization and $4.1M of share-based compensation. Working capital and other items added $3.2M.
Questions
What was Xeris Biopharma Holdings' revenue in the first quarter 2026?
Xeris Biopharma Holdings (XERS) reported revenue of $83.1M for the first quarter 2026 (Q1 2026), +38% from a year earlier and -3% from the quarter before.
Was Xeris Biopharma Holdings profitable in the first quarter 2026?
Operating profit was $7.9M (9.5% of revenue) and net earnings $2.2M.